Tenderwize
Retour à la recherche

Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2028 · 704 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab

75/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

75 / 100

Complexité

30 / 100

Facteurs de risque

No estimated contract value or volume is provided. Potential revenue is unknown.

The contract automatically ends upon patent expiry or loss of market exclusivity, potentially shortening the contract t...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclude discount agreements (Rabattverträge) for the active substance Tralokinumab with all eligible pharmaceutical entrepreneurs.
  • Pharmaceutical supply to insured persons of TK and participating health insurers.
Afficher le résumé complet

This is an Open House procedure by Techniker Krankenkasse (TK) and affiliated health insurers to conclude discount agreements (Rabattverträge) for the active substance Tralokinumab, in accordance with § 130c SGB V. The procedure is open to all qualified pharmaceutical entrepreneurs who hold a valid marketing authorization for Tralokinumab. Contracts are offered on standardized, non-negotiable terms with no exclusivity. The contract duration is up to 24 months, starting 01 August 2026 and ending at the latest 31 July 2028. The procedure is not a public procurement under EU law; it remains continuously open for new participants throughout its validity. No estimated contract value, award criteria, or competitive selection are specified – eligible participants are automatically accepted upon confirming their eligibility. Documents are available but were not analyzed. Place of performance is throughout Germany.

Risques

No estimated contract value or volume is provided. Potential revenue is unknown.

The contract automatically ends upon patent expiry or loss of market exclusivity, potentially shortening the contract t...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.
  • Must have seat in Germany, another EU Member State, or EEA state (§ 9 Abs. 2 AMG).
  • Must hold a valid marketing authorization for Tralokinumab or be legally entitled to market the product.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab

Discount agreement for Tralokinumab. Standardized terms, no exclusivity, available to all qualified pharmaceutical entrepreneurs holding a valid marketing authorization for the active substance.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jul 2026 - Jul 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 30, 2028

Détails de la procédure

Date de publication
17 Jun 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
418152-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3